Applied Therapeutics Shareholders Pursue Class Action Settlement, Fiduciary Duties Alleged.
ByAinvest
Wednesday, Sep 10, 2025 9:41 am ET1min read
APLT--
The class action lawsuit alleges that Applied Therapeutics, through its officers, provided positive statements to investors while disseminating false and materially misleading information about the Phase III INSPIRE trial. Notably, the complaint highlights electronic data capture issues and a dosing error in the dose-escalation phase of the study, which were not disclosed to investors. These statements, it is alleged, caused shareholders to purchase the company's securities at artificially inflated prices.
On August 25, 2025, the parties involved in the lawsuit reported to the Court that they had agreed to settle the securities fraud class action. Shareholders who purchased Applied Therapeutics shares before January 3, 2024, and still hold them today, are encouraged to visit https://grabarlaw.com/the-latest/applied-therapeutics-shareholder-investigation/ or contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085 to learn more about seeking corporate reforms, the return of funds back to the company, and a court-approved incentive award at no cost to them whatsoever [1].
This settlement is part of a broader investigation by Grabar Law Office that also involves shareholders of Elevance Health Inc. (NYSE: ELV), LifeMD, Inc. (NASDAQ: LFMD), and Quantum Corporation (NASDAQ: QMCO). Each of these companies is facing similar allegations regarding breaches of fiduciary duties and false or misleading statements to investors [1].
For more information about the class action lawsuits, shareholders are advised to visit the Grabar Law Office website or contact Joshua Grabar directly.
Applied Therapeutics shareholders who purchased shares before Jan. 3, 2024, can seek corporate reforms, a return of funds, and an incentive award through a class action lawsuit. The investigation concerns allegations that officers and directors breached fiduciary duties. Shareholders can visit grabarlaw.com or contact Joshua Grabar at jgrabar@grabarlaw.com for more information.
Philadelphia, Sept. 10, 2025 — Applied Therapeutics (NASDAQ: APLT) shareholders who purchased shares before January 3, 2024, have an opportunity to seek corporate reforms, a return of funds, and an incentive award through a class action lawsuit. The investigation, conducted by Grabar Law Office, concerns allegations that certain officers and directors breached their fiduciary duties [1].The class action lawsuit alleges that Applied Therapeutics, through its officers, provided positive statements to investors while disseminating false and materially misleading information about the Phase III INSPIRE trial. Notably, the complaint highlights electronic data capture issues and a dosing error in the dose-escalation phase of the study, which were not disclosed to investors. These statements, it is alleged, caused shareholders to purchase the company's securities at artificially inflated prices.
On August 25, 2025, the parties involved in the lawsuit reported to the Court that they had agreed to settle the securities fraud class action. Shareholders who purchased Applied Therapeutics shares before January 3, 2024, and still hold them today, are encouraged to visit https://grabarlaw.com/the-latest/applied-therapeutics-shareholder-investigation/ or contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085 to learn more about seeking corporate reforms, the return of funds back to the company, and a court-approved incentive award at no cost to them whatsoever [1].
This settlement is part of a broader investigation by Grabar Law Office that also involves shareholders of Elevance Health Inc. (NYSE: ELV), LifeMD, Inc. (NASDAQ: LFMD), and Quantum Corporation (NASDAQ: QMCO). Each of these companies is facing similar allegations regarding breaches of fiduciary duties and false or misleading statements to investors [1].
For more information about the class action lawsuits, shareholders are advised to visit the Grabar Law Office website or contact Joshua Grabar directly.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet